Literature DB >> 23159616

The liver X receptor promotes macrophage differentiation and suppresses osteoclast formation in mouse RAW264.7 promyelocytic leukemia cells exposed to bacterial lipopolysaccharide.

Kirsten M Robertson Remen1, Jan-Åke Gustafsson, Göran Andersson.   

Abstract

Lipopolysaccharide (LPS), the principal component of Gram-negative bacterial cell walls, is a stimulator of osteoclastogenesis and thus a key factor in inflammatory bone loss. We have recently reported that the important cholesterol and inflammatory regulator, liver X receptor (LXRα/β), can potently inhibit osteoclast formation from bone marrow-derived osteoclast precursors in a bacterial/LPS environment. In this manuscript, we further studied the effect of the LXR agonist GW3965 on osteoclast differentiation in RAW264.7 promyelocytic leukemia cells exposed to LPS. We found that not only did activation of the LXR potently inhibit the formation of TRAP-positive osteoclast-like cells, but promoted a population of TRAP-negative mononuclear cells with high phagocytic activity. We observed reduced expression of the osteoclast markers TRAP/Acp5, Ctsk, Calcr and Oscar after 3-4days of GW3965 treatment, coinciding with an increase in the expression of the anti-osteoclastogenic factor Irf8. Expression of the macrophage/phagocytic marker Cd68 was increased, however the "classical" macrophage markers F4/80 and Cd14 and the "alternatively" activated macrophage markers Tgfβ and Il10 were not altered. Further, activation of LXR increased the expression of the macrophage survival gene AIM/SPα, a known LXR target gene, and osteoclast/macrophage-related markers (Mitf, Pu.1, Usf1/2, Ostm1 and Mfr). Although Akt phosphorylation was reduced, GW3965 seemed to act independently of MAPKs (p38, ERK, JNK) and NFκB, and had no inhibitory effect on cytokine expression (Tnfα, Il6, or Il1β). Our results indicate that activation of the LXR not only inhibits the differentiation of osteoclast-like cells from RAW264.7 cells in a bacterial/LPS environment, but is also involved in the fate determination of myeloid progenitor cells into macrophages with high phagocytic capacity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159616     DOI: 10.1016/j.bbrc.2012.11.021

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Liver X receptors contribute to periodontal pathogen-elicited inflammation and oral bone loss.

Authors:  N Huang; Y B Shaik-Dasthagirisaheb; M P LaValley; F C Gibson
Journal:  Mol Oral Microbiol       Date:  2015-06-09       Impact factor: 3.563

2.  Germacrone induces apoptosis in human hepatoma HepG2 cells through inhibition of the JAK2/STAT3 signalling pathway.

Authors:  Yun-Yi Liu; Qian Zheng; Bin Fang; Wei Wang; Feng-Yun Ma; Sadia Roshan; Amal Banafa; Ming-Jie Chen; Jun-Li Chang; Xiao-Min Deng; Ke-Xiu Li; Guang-Xiao Yang; Guang-Yuan He
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

3.  Gene expression changes in human mesenchymal stem cells from patients with osteoporosis.

Authors:  Lianyong Liu; Qingyun Zhu; Jingnan Wang; Qian Xi; Hongling Zhu; Mingjun Gu
Journal:  Mol Med Rep       Date:  2015-03-19       Impact factor: 2.952

4.  Vaccaria hypaphorine alleviates lipopolysaccharide-induced inflammation via inactivation of NFκB and ERK pathways in Raw 264.7 cells.

Authors:  Haijian Sun; Weiwei Cai; Xu Wang; Yanling Liu; Bao Hou; Xuexue Zhu; Liying Qiu
Journal:  BMC Complement Altern Med       Date:  2017-02-20       Impact factor: 3.659

Review 5.  Immune Cells and Inflammation in Diabetic Nephropathy.

Authors:  Zihan Zheng; Feng Zheng
Journal:  J Diabetes Res       Date:  2015-12-28       Impact factor: 4.011

6.  LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer.

Authors:  Katherine J Carpenter; Aurore-Cecile Valfort; Nick Steinauer; Arindam Chatterjee; Suomia Abuirqeba; Shabnam Majidi; Monideepa Sengupta; Richard J Di Paolo; Laurie P Shornick; Jinsong Zhang; Colin A Flaveny
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.